Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Gains from Investment Securities (2019 - 2025)

Vivos Therapeutics has reported Gains from Investment Securities over the past 7 years, most recently at $11000.0 for Q4 2025.

  • Quarterly Gains from Investment Securities rose 120.0% to $11000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.5 million through Dec 2025, down 133.33% year-over-year, with the annual reading at $287.0 for FY2025, 99.97% down from the prior year.
  • Gains from Investment Securities was $11000.0 for Q4 2025 at Vivos Therapeutics, up from $5000.0 in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $2.9 million in Q3 2021 and troughed at -$1.6 million in Q3 2023.
  • The 5-year median for Gains from Investment Securities is $133500.0 (2021), against an average of $271425.0.
  • Year-over-year, Gains from Investment Securities surged 28610.0% in 2021 and then plummeted 7117.54% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $2.9 million in 2021, then crashed by 90.98% to $259000.0 in 2022, then crashed by 66.8% to $86000.0 in 2023, then tumbled by 94.19% to $5000.0 in 2024, then soared by 120.0% to $11000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Gains from Investment Securities are $11000.0 (Q4 2025), $5000.0 (Q4 2024), and $105000.0 (Q3 2024).